The global Cystic Fibrosis Therapeutics market size is expected to be worth around US$ 23.9 billion by 2030, according to a new report by Vision Research Reports.
The global Cystic Fibrosis Therapeutics market size was valued at US$ 13.56 billion in 2020 and is anticipated to grow at a CAGR of 26.7 % during forecast period 2021 to 2030.
The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.
The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.
Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.
Based on the drug class, the market is segmented into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. The primary consideration in the treatment of CF is maintaining the lung function while controlling respiratory infection and clearing airways of mucus, managing the nutritional therapy, and controlling the complications. Kalydeco was the first CFTR modulator drug, which was launched in 2012 in the U.S. As of 2014, it was the only CFTR modulator drug in the market.
In 2016, CFTR modulators accounted for the largest revenue with a share of approximately 47.3% owing to the launch of new drug Orkambi. This drug is responsible for correcting the function of defective protein caused by the CF gene. This drug class directly cures the underlying cause of the disease. The product launch in 2015 is one of the key factors that can be accounted for its share. Moreover, CFTR modulators are expected to grow with a lucrative growth rate of 24.1% over the forecast period.
This drug class is expected to be the fastest growing segment owing to the growing number of drugs in the pipeline. Some of the CFTR modulators drugs combinations that are in pipeline are as follows:
CTP-656 (Deuterated ivacaftor)
Based on the route of administration, the market is segmented into oral route and inhaled drugs. Oral route accounted for the largest share of nearly 63.7% in 2016 owing to the advantages associated with its administration such as convenience and ease of consumption without the help of a healthcare professional. Growing awareness in emerging economies about the benefits of oral drugs, which include CFTR modulators and pancreatic enzyme supplements is one of the crucial factors anticipated to propel the demand for these drugs.
Some of the approved therapeutics that are administered orally are CFTR modulators such as KALYDECO and ORKAMBI and pancreatic enzyme supplements such as Creon/Zenpep, PERTZYE, Ultresa, and Viokace. High commercial availability and huge demand for these drugs to treat CF are expected to drive the oral drug segment. According to the U.S. patient registry 2015, hypertonic saline was prescribed to 21.5% children falling under the age group of 0 to 3 years and 41.9% children in the age group of 3 to 5 years. Increasing prevalence of CF among new born babies is one of the key factors responsible for growing demand for oral drug formulation.
Increasing number of clinical trials to expand the patient base is one of the key factors anticipated to boost the market. Moreover, the segment is expected to emerge with a lucrative growth rate of 20.1% over the forecast period. Growing number of private and public players investing in this segment is also one of the factors expected to boost the demand for oral medication.
Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest revenue of USD 2,396.4 million in 2016. CF is most prevalent in North America as most of the people affected with CF are of Caucasian descent. Furthermore, initiatives taken by CF Foundation and Cystic Fibrosis Canada are one of the key reasons that can be accounted for its largest share.
However, Asia Pacific is expected to be the fastest growing segment with a lucrative growth rate of 18.8%. Although the incidence of CF is less frequently reported in the Asia Pacific region due to underdiagnoses and lack of country-specific CF patient registries, rising awareness about CF disorders & treatment options is expected to boost this segment over the forecast period. Economic development in this region and improving healthcare facilities are expected to boost the market over the forecast period.
Growing awareness amongst healthcare professionals & patient population regarding advanced therapeutics in the market & their advantages over the existing drug portfolio is one of the crucial factors anticipated to boost the market in the coming years. Currently, the availability of CF-specific drugs is low, however, growing approvals and product launches in this market are anticipated to impel growth.
AbbVie, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Alcresta Therapeutics, Inc.; Allergan; and AstraZeneca.
Drug Class Outlook
Pancreatic enzyme supplements
Route of Administration Outlook
Middle East & Africa
The Cystic Fibrosis Therapeutics market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Cystic Fibrosis Therapeutics market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Cystic Fibrosis Therapeutics market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cystic Fibrosis Therapeutics market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Cystic Fibrosis Therapeutics market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Cystic Fibrosis Therapeutics capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Cystic Fibrosis Therapeutics by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Cystic Fibrosis Therapeutics market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Cystic Fibrosis Therapeutics market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Cystic Fibrosis Therapeutics market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Cystic Fibrosis Therapeutics industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Cystic Fibrosis Therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Cystic Fibrosis Therapeutics market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Cystic Fibrosis Therapeutics market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Cystic Fibrosis Therapeutics market. These factors have benefited the growth of the global market for Cystic Fibrosis Therapeutics. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Cystic Fibrosis Therapeutics. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Cystic Fibrosis Therapeutics are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Audiology Devices Market (By Product: Hearing Aids, Cochlear Implants; By Technology: Digital, Analog; By Sales Channel: Retail, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
Micro-pumps Market (By Product: Mechanical, Non-mechanical; By Application: Drug Delivery, Medical Devices; By End Use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
U.S. Behavioral Health Care Software And Services Market (By Component: Software, Support Services; By Delivery Model; By Function; By End Use) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
Medical Imaging Market (By Product: X-ray, CT, MRI, Ultrasound; By End-use: Hospitals, Diagnostic Imaging Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
Medical Imaging Phantoms Market (By Device Type: X-ray, Ultrasound, CT, MRI; By End Use; By Material: Simulating Organs, False Organs) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...